Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | MLYCD | O95822 | 1/20 | 0.43 |
| ▸ | ESRRG | P62508 | 1/20 | 0.43 |
| ▸ | USP1 | O94782 | 2/20 | 0.42 |
| ▸ | ATR | Q13535 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | TNKS | O95271 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
| ▸ | ITK | Q08881 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23471013 | 0.86 | NAMPT (0.50) | NAMPTHDAC4DRD2MLYCDESRRG | |
| SCHEMBL18770116 | 0.86 | MLYCD (0.54) | NAMPTCA1CA2MLYCDHDAC1 | |
| SCHEMBL31247841 | 0.85 | CA1 (0.41) | NAMPTHDAC4DRD2CA1CA2 | |
| SCHEMBL23471114 | 0.84 | LOXL2 (0.51) | NAMPTHDAC4DRD2MLYCDESRRG | |
| SCHEMBL4693228 | 0.82 | NAMPT (0.52) | NAMPTHDAC4DRD2CA1CA2 | |
| SCHEMBL1448569 | 0.82 | CA1 (0.47) | HDAC4DRD2CA1CA2MLYCD | |
| SCHEMBL12302019 | 0.82 | NAMPT (0.52) | NAMPTHDAC4DRD2MLYCDATR | |
| SCHEMBL31003180 | 0.82 | NAMPT (0.52) | NAMPTHDAC4DRD2MLYCDATR | |
| SCHEMBL28506371 | 0.81 | NAMPT (0.51) | NAMPTHDAC4DRD2MLYCDATR | |
| SCHEMBL4695349 | 0.81 | NAMPT (0.54) | NAMPTHDAC4DRD2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011285-A1 | CYP11A1 INHIBITORS | ORION CORPORATION (FI) | 2025-01-09 | — | — | US | disclosed |
| US-20230192677-A1 | CYP11A1 INHIBITORS | ORION CORPORATION (FI) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192677-A1 | CYP11A1 INHIBITORS | CYP11B1, CYP11B2, CYP17A1 | NAMPT 981/4885HDAC4 2121/4885DRD2 4791/4885 |
| US-20250011285-A1 | CYP11A1 INHIBITORS | CYP11B1, CYP19A1, CYP11B2 | NAMPT 2064/4885HDAC4 2122/4885DRD2 3825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.